PERTH, Australia, Oct. 2, 2013 /PRNewswire/ -- Regenerative medicine company, Orthocell Limited (Orthocell), today announced the results of its unprecedented and successful clinical trial for the treatment of tendon injuries using its patented stem cell technology. Tendon injuries are one of the most common causes of occupational and sporting disability and current clinical treatments are only moderately effective.
Orthocell's new technique is known as Autologous Tenocyte Implantation (Ortho-ATIT) and involves biopsy of the patient's own healthy tendon, isolation and cultivation of tendon stem cells from the biopsy in a special laboratory and then injection of these cells back to the injured tendon. The process takes about 20-minutes and is less invasive than surgery.
The company has received international profiling and recognition in the prestigious American Journal of Sports Medicine (AJSM), with a peer reviewed publication of the world first study on Ortho-ATIT stem cell technology for regeneration of damaged human tendon.
The AJSM, which is ranked as the world's number one journal for orthopaedics and sports medicine, published outcomes of the clinical trial last week. The data demonstrates that Orthocell's novel technology for repairing tendons was a safe and effective procedure that enables a reduction in pain and repairs tendon in severe chronic resistant tendon injury, like tennis elbow. The patients treated in the study, had failed at least one previous therapy including physiotherapy and corticosteroid injection. Patients achieved significant improvement in function and structural integrity of the tendon after the Ortho-ATIT tendon stem cell injection.Orthocell Managing Director Paul Anderson said the clinical study indicates great potential for the Ortho-ATIT stem cell tendon repair. "The AJSM paper is a benchmark study that validates the repair of tendon using tendon derived stem cells. We are now focussing our efforts on offering this world class treatment more widely to patients throughout Australasia, and we are also investigating new potential markets overseas," said Mr Anderson.